ro6895882
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2013 (NCT02004106)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- ro6895882
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02004106 | Phase 1 | Dec 31, 2013 | Roche |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1